Bio-Thera Solutions, a commercial-stage biopharmaceutical company developing a pipeline of innovative therapies and biosimilars, and Gedeon Richter have reached an exclusive commercialization and license agreement for BAT2206, a biosimilar candidate to Stelara, it was announced on the website of the Budapest Stock Exchange.
Under the agreement, Bio-Thera will maintain responsibility for development, manufacturing, and supply of BAT2206 and Bio-Thera has filed BAT2206 for regulatory approval with EMA on July 1, 2024. Richter will have exclusive rights to commercialize the product in the European Union (EU), the UK, Switzerland and selected other countries.
Bio-Thera will receive an upfront payment of USD 8.5 million, as well as further development and commercial milestones of up to USD 101.5 million, subject to the fulfillment of certain conditions.
“We are pleased to establish this partnership with Gedeon Richter for BAT2206,” Bio-Thera CEO Dr. Shengfeng Li said. “BAT2206 is an important product to Bio-Thera and we believe that Richter is the right partner for helping Bio-Thera bring BAT2206 to the most patients possible in the EU and the UK.”
Dr. Erik Bogsch, Head of the Biotechnology Business Unit of Richter, stated that “we are pleased to announce that Richter has made another important step towards building a robust biosimilar portfolio across its core commercial region. Subsequent to the acquisitions made earlier this year and the recent news of our denosumab filing, the current deal with Bio-Thera reinforces Richter’s presence and biosimilar portfolio in Europe.”
Leave a Reply Cancel reply
Top 5 Articles
- UNITED - Passion, Show & Party May 23, 2024
- Gedeon Richter to Sell Chinese Biosimilar Product in Europe October 9, 2024
- Cherishing a Long-Standing Friendship July 2, 2024
- 2024 Sustainable Future Awards Presented October 10, 2024
- Measurable Results for Inclusion June 19, 2024
No comment yet. Be the first!